Custom Lucite commemorative marking an exclusive licensing agreement between Soligenix and SciClone.
(6ALJC10)
Whether you’re celebrating a funding round, research collaboration, FDA-approval, or commemorating a deal in the biotech space, you’ll find inspiration in the custom designs below.
Custom Lucite commemorative marking an exclusive licensing agreement between Soligenix and SciClone.
(6ALJC10)Lucite embedment featuring test tube marking the acquisition of Lodi, Italy-based Euticals. Euticals is focused on custom synthesis and the manufacture of active pharmaceutical ingredients. (6LACC42). Â Follow this link to see other examples of Lucite embedments.
Lucite commemorative marking a research and development joint venture between Massachusetts-based CRISPR, and German drug company Bayer. The collaboration will center on CRISPR’s gene-editing technology, and focus on the treatment of conditions such as congenital heart disease, blood disorders, and blindness.
(6AGP903)Vat-themed deal toy commemorating the issuance of third-party warrants to the Evolution Biotech Fund.
(6ALMD34)Lucite tombstone marking legal representation of Daylight Solutions in a stock issue. Â The San Diego-based is a developer of molecular detection and imaging systems with applications in such areas as research, life sciences, and defense.
(6ADL595)Custom commemorative marking the global collaboration between Janssen Biotech and TESARO involving the treatment of prostate cancer, with a design incorporating a spinning heart.
(6ALR124)Custom deal toy commemorating the initial public offering of Spring Bank Pharmaceuticals, a clinical-stage biopharmaceutical company based in Hopkinton, Massachusetts. The firm has focused on small-molecule therapies for hepatitis B and viral diseases.
(6AKLA83)Beginning on this page, you’ll find galleries with over 90 images of financial tombstones and deal toys from the biotech and life sciences space. You’ll find a number of custom designs playing off visual elements commonly associated with this space, including DNA strands, pills, lab beakers, periodic tables, as well as ones incorporating actual drug vials.
As you might also expect, you’ll see a number of deal toys involving internationally recognized firms and players. These include Takeda Pharmaceutical, Horizon Therapeutics, Gilead Sciences, Roche, Neurocrine, and Bayer. You’ll see as well tombstones commemorating transactions common to this sector involving these and other firms: joint ventures, licensing deals, and development and commercialization agreements.
But you’ll also notice a number of deals commemorated here that may involve far less familiar firms. These include the acquisition of a Dutch company focused on live-cell imaging analytics, and one of an Illinois-based gene therapy firm devoted to the treatment of a rare genetic disorder; the initial public offering of an Australian developer of radiopharmaceutical cancer therapies, and the IPO of a Norwegian biotech making use of marine compounds such as herring roe extract; early-stage funding for a Philadelphia gene engineering startup, and the IPO of an Israeli firm focused on medical applications for lipid-based compounds.
You’ll also notice in these galleries designs not related to any financial transaction. These celebrate a range of awards and employee recognition pieces honoring successful clinical trials, Food and Drug Administration (FDA) and New Drug Application (NDA) submissions, research collaborations and partnerships, and product development milestones.
